DrugMonkey doesn't think much of the new NIH rules to address financial conflict of interest among researchers. In fact, he says, the tighter rules "will do absolutely nothing about real COI." For one thing, DrugMonkey says, lowering the reporting threshold from $10,000 to $5,000 won't do anything about the PIs who caused scandal and were investigated by Congress for making hundreds of thousands of dollars from big pharma without reporting it.